Compare Cassava Sciences Inc (FLNA) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Match Group Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Match Group Inc trades at $41.48 (market cap $9.37B). The key difference: Match Group Inc is far larger — about 237.8× Cassava Sciences Inc's market cap, and Match Group Inc pays a 1.96% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Match Group Inc for 115 Days on average.
| FLNA | MTCH | |
|---|---|---|
Market Cap | $39.40M | $9.37B |
Volume | 759,018 | 2,544,041 |
Sector | Health | Media |
52-Week High | $4.64 | $44.40 |
52-Week Low | $0.68 | $28.90 |
Typical Hold Time | 37 Days | 115 Days |
Enterprise Value | -$43.28M | $12.34B |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Match Group (MTCH) trades at $41.50, up 2.17% with a bullish technical outlook. The stock shows strong fundamentals with 74.8% gross margins and consistent earnings beats in recent quarters. Revenue remains stable at $3.5B while net income margin improved to 20.17% in 2025. Analyst consensus is bullish with a $42.29 price target, and institutional activity shows continued interest despite recent selling by some advisors.
MTCH presents a compelling investment case with reasonable valuation (P/E 14.48) and strong cash flow generation. Key risks include high debt levels ($3.85B) and competitive pressures in the dating app market. The company's product innovation and Hinge's growth provide upside potential, though execution risks and market saturation concerns warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
